Optical Coherence Tomography Angiography Evaluation Of Patients Taking Hydroxychloroquine
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Hydroxychloroquine Retinopathy. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study aims to evaluate retinal and choroidal microvascular changes using optical coherence tomography angiography (OCTA) in patients receiving hydroxychloroquine therapy. Hydroxychloroquine is commonly used in the treatment of autoimmune diseases and may cause retinal toxicity with long-term use. OCTA is a non-invasive imaging modality that allows detailed assessment of retinal vascular changes.
Detailed description
Hydroxychloroquine is widely prescribed for the management of autoimmune and rheumatologic diseases. Long-term use of hydroxychloroquine has been associated with retinal toxicity, which may lead to irreversible visual impairment if not detected early. Conventional screening methods include fundus examination, automated visual field testing, and spectral-domain optical coherence tomography.
Optical coherence tomography angiography (OCTA) is a non-invasive imaging technique that enables quantitative and qualitative assessment of retinal and choroidal microvasculature. This study is designed to evaluate OCTA parameters in patients receiving hydroxychloroquine therapy.
Patients undergoing hydroxychloroquine treatment will be evaluated using OCTA imaging. Retinal vascular parameters will be analyzed and correlated with clinical variables such as duration of treatment and cumulative hydroxychloroquine dose. The findings of this study may contribute to improved understanding of early microvascular changes associated with hydroxychloroquine exposure and the potential role of OCTA in retinal toxicity screening.
Primary outcome measures
- Superficial Capillary Plexus Vessel Density (SCP) [Time frame: Day 1]
- Deep Capillary Plexus Vessel Density (DCP) [Time frame: Day 1]
Eligibility criteria
Inclusion criteria
- Adults (≥18 years old) with documented HCQ therapy for ≥1 year.
- Stable systemic disease under medical supervision.
Exclusion criteria
- -patients with media opacity.
- Any pre-existing retinal or optic nerve disease (e.g., diabetic retinopathy, AMD, myopic degeneration).
- History of intraocular surgery or trauma.
- Uncontrolled systemic vascular diseases (e.g., hypertension)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07409740 · SMohamedAhmed